We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Phagocyte Mutation Interferes with Immune System Control

By LabMedica International staff writers
Posted on 24 Jan 2018
A mutation causing production of an inactive form of the CX3CR1 (C-X3-C motif chemokine receptor 1) protein in immune system mononuclear phagocytes has been identified as major contributor to the development of Crohn's disease and other types of inflammatory bowel disease (IBD).

Intestinal fungi are an important component of the gut microbiota, and recent studies have unveiled their potential in modulating host immune homeostasis and inflammatory disease. More...
While CX3CR1+ mononuclear phagocytes (MNPs) had been identified as being essential for the initiation of innate and adaptive immune responses to intestinal fungi, and it was known that CX3CR1+ MNPs expressed antifungal receptors and activated antifungal responses, the mechanisms governing immunity to gut fungal communities (mycobiota) remained unknown.

To further understanding in this important area, investigators at Weill Cornell Medicine (New York, NY, USA) used chemical means to induce colitis in mice, and then infected them with fungi to determine whether the fungal cells would overgrow in the mouse gut and increase the severity of the illness.

Results published in the January 12, 2018, issue of the journal Science revealed that mice lacking gut CX3CR1+ phagocytes were more susceptible to intestinal disease than mice that had functional antifungal phagocytes. Antifungal drug treatment significantly reversed symptoms of the disease in mice lacking CX3CR1+ phagocytes, indicating that fungal overgrowth was responsible for the severe response.

The investigators analyzed phagocyte function in a group of more than 500 Crohn’s disease patients. They identified a missense mutation in the gene encoding CX3CR1 and found that it was associated with impaired antifungal responses.

"Our findings show that these CX3CR1+ cells are also essential for the initiation of immune responses to gut fungi, and regulate the composition of the gut mycobiome," said senior author Dr. Iliyan Iliev, assistant professor of microbiology and immunology at Weill Cornell Medicine. "Fungal DNA is hard to access and analyze using standard molecular biology techniques, but we have recently developed much better tools for doing so, and have now taken this further by visualizing fungal-host interactions in the gut. After discovering that fungi might be involved in the pathology of IBD, one of the big questions in the field has been how to identify patients who would benefit from antifungal co-therapy, and our finding suggests a way to do that."

Related Links:
Weill Cornell Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.